Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature
Journal of Immunology Research · 2024-01 · 2024 (1)
DOI: 10.1155/2024/8481761 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 24.10.2024. Verfasst von Angus Nnamdi Oli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka 420211, Nigeria. Hauptthemen laut MEDLINE: Neoplasms, Tumor Microenvironment, Immunotherapy, Cancer Vaccines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Malignant tumors, characterized by uncontrolled cell proliferation, are a leading global health challenge, responsible for over 9.7 million deaths in 2022, with new cases expected to rise to 35 million annually by 2050. Immunotherapy is preferred to other cancer therapies, offering precise targeting of malignant cells while simultaneously strengthening the immune system’s complex responses. Advances in this novel field of science have been closely linked to a deeper knowledge of tumor biology, particularly the intricate interplay between tumor cells, the immune system, and the tumor microenvironment (TME), which are central to cancer progression and immune evasion. This review offers a comprehensive analysis of the molecular mechanisms that govern these interactions, emphasizing their critical role in the development of effective immunotherapeutic products. We critically evaluate the current immunotherapy approaches, including cancer vaccines, adoptive T cell therapies, and cytokine‐based treatments, highlighting their efficacy and safety. We also explore the latest advancements in combination therapies, which synergistically integrate multiple immunotherapeutic strategies to overcome resistance and enhance therapeutic outcomes. This review offers key insights into the future of cancer immunotherapy with a focus on advancing more effective and personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka 420211, Nigeria.
- Department of Biological Sciences, University of Illinois, Chicago, 845 West Taylor, Chicago 60607, Illinois, USA.
- Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Federal University Oye Ekiti, Oye, Ekiti State, Nigeria.
- National Biotechnology Development Agency, Abuja 900211, Nigeria.
- Department of Pharmaceutical Science, North Carolina Central University, Durham 27707, North Carolina, USA.
ORCID-Profile: Angus Nnamdi Oli, Samson Adedeji Adejumo, Adekunle Babajide Rowaiye, Joyce Oloaigbe Ogidigo, Jarrad Hampton-Marcell, Gordon C Ibeanu
Zitieren
APA
Oli, A. N., Adejumo, S. A., Rowaiye, A. B., Ogidigo, J. O., Hampton-Marcell, J., & Ibeanu, G. C. (2024). Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature. Journal of Immunology Research, 2024(1). https://doi.org/10.1155/2024/8481761
Vancouver
Oli AN, Adejumo SA, Rowaiye AB, Ogidigo JO, Hampton-Marcell J, Ibeanu GC. Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature. Journal of Immunology Research. 2024;2024(1). doi:10.1155/2024/8481761
BibTeX
@article{Oli2024,
author = {Oli, Angus Nnamdi and Adejumo, Samson Adedeji and Rowaiye, Adekunle Babajide and Ogidigo, Joyce Oloaigbe and Hampton-Marcell, Jarrad and Ibeanu, Gordon C},
title = {Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature},
journal = {Journal of Immunology Research},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/8481761}
}
EUVIMED